DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Clinical trial NCT07472517 · RECRUITING

Trial details

NCT number: NCT07472517
Sponsor: Boehringer Ingelheim
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Start date: 2026-04-13
Primary completion: 2028-09-09
Enrollment: 670

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.